ANORO® is the commercial brand name of Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation, a fixed-dose dual long-acting bronchodilator combining a long-acting muscarinic antagonist and a long-acting β₂ agonist developed by GSK. It produces persistent bronchodilation by targeting two distinct airway receptors to relieve sustained bronchoconstriction.
Main Indications
Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Clinical Research
Global multicenter phase III trials demonstrated that this dual bronchodilator combination improves lung function and alleviates dyspnea compared with single long-acting bronchodilators;
Clinical trials enrolling Asian participants achieved consistent therapeutic efficacy and safety results matching global study populations;
Long-term observational studies confirmed stable respiratory symptom control and reduced risk of COPD moderate and severe exacerbations with continuous administration.
Common Side Effects
Severe but important risks: Paradoxical bronchospasm, severe hypersensitivity reactions, urinary retention and glaucoma;
Common mild adverse reactions: Headache, dry mouth, palpitations, nasopharyngitis, cough and arthralgia.
Approval Status in China
Original drug ANORO® (Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation) was officially approved for marketing in China in 2014. It is currently a prescription inhaled medicine for chronic obstructive pulmonary disease.
Buy ANORO (Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
